HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK MHRA Approves Sale Of Reckitt’s Nuromol Outside Pharmacy

Executive Summary

Reckitt's Nuromol is the first combination of paracetamol and ibuprofen approved for sale in the UK outside of pharmacy. The company has also been granted one year of exclusivity for the data used to secure the reclassification.

You may also be interested in...



Reckitt Seeks UK General Sale Status For Nuromol Paracetamol + Ibuprofen Combo

Reckitt's application for a P-to-GSL switch of its Nuromol paracetamol and ibuprofen combination painkiller in the UK is out for consultation until 3 June. 

In First For US OTC Market, Advil Line Extension Combines Ibuprofen And Acetaminophen

CDER approval of Pfizer's NDA introduces a new formulation to the US OTC market. Labeling for was approved with the requirement of adding bullet points for an “Acetaminophen liver damage warning” and an “NSAID stomach bleeding warning” on all immediate containers.

Reckitt Targets UK's Painful ‘Tweens’ With Double-Strength Nurofen

Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."

Related Content

Topics

UsernamePublicRestriction

Register

RS151665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel